Colorectal Cancer (CRC)Colorectal Cancer and Pre-cancer PolypsBlood Stream InfectionAnaerobic InfectionBacteriaemia
Investigational drug(s) / intervention(s)
Colon capsule endoscopy
Colon capsule endoscopy: PillCam Colon 2
Study summary
The goal of this observational study is to diagnose colorectal cancer or precancerous tumors in participants over the age of 18 hospitalized with blood stream infection with anaerobic gut-associated bacteria. The main question it aims to answer is:
• How prevalent is cancer and precancerous tumors in the large intestines and rectum in patients with anaerobic bacteremia? Participants will be offered an examination using colon capsule endoscopy 4-8 weeks after discharge.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Older than 18 years
* Blood culture with growth of one or more of the following bacterial genera Bacteroides, Clostridium, Filifactor, Fusobacterium, Gemella, Granulicatella, Parvimonas, Peptostreptococcus, Prevotella, Solobacterium, Peptoniphilus, Ruminococcus, Finegoldia and Streptococcus.
* Able to provide oral and written informed consent
* Able to read and speak Danish
Exclusion Criteria:
* Prior colorectal cancer diagnosis
* History of stenosis of the gastrointestinal tract
* Previous treatment of inflammatory bowel disease
* Previous major surgery of the gastrointesinal tract (e.g. gastric bypass)
* Colostomy
* Pacemaker/ICD
* Pregnancy or breastfeeding
* Allergies to the bowel preparation regimen
* Severe kidney disease
* Focus of infection in skin and soft tissue or outside the truncus (e.g. decubitus, diabetic foot ulcer)
* Tumor in the colon or rectum at diagnostic imaging
* Transfer to other hospital outside the region
Primary outcome measure(s)
Colorectal cancer and precancerous tumors — 4-8 weeks after hospitalization with anaerobic gut-associated bacteria Prevalence of colorectal cancer and precancerous tumors using colon capsule endoscopy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.